Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Qlife Holding AB (publ) ("Qlife" or the "Company") recently announced a restructuring and new financing to support its strategic goals. The Company is pleased to report that its operational plan with its partner Hipro Biotechnology ("Hipro") in China is progressing as planned, with the production of Egoo consumables-EgooCapsule (Biochemistry reagents) and EgooCollect (Blood-to-Plasma filtration)-now established at the partner site. The target is to reach a capacity of 1 million in 2025 and 10 million within 3 years. This production capability will support clinical trial efforts and future sales.
The Company reports that, in collaboration with its partner Hipro, progress has been made on the four key objectives set for their partnership. The integration and validation of Hipro biochemistry reagents on the Egoo Health platform have been successfully completed, and the first biomarker, CRP, is currently in clinical trials. Additionally, the commencement of consumables production represents a significant operational milestone.
1. Integration of biochemistry reagents
2. Production of Egoo Health in China
3. Regulatory approval in China
4. Distribution and sales in China
Thomas Warthoe, CEO comments: "It has been a bottleneck to ship consumables to China in order for Hipro to continue the effort towards first approval - therefore it is a high priority to get local production established so that everything can move forward more diligently. This means that goal 1 and 2 on our milestone list is achieved - and from now on we are focused on getting the first approval, starts sales in China and move more tests through the clinic".
The production of the Egoo instrument remains in Scandinavia for the time being, while the production of consumables and scale-up to high volumes is now handled by Hipro.
The focus on accessing the Chinese at-home hospital segment and other decentralized testing environments in China, where people can access daily clinical biomarker testing, is the materialization of Qlife's strategic plan to establish a foothold in major global markets.
About Egoo
Egoo Health enables advanced clinical-grade biomarker testing at home. The aim is to give people access to important health data at the clinical-grade level. Egoo Health is an integrated platform, consisting of a small diagnostic device, a blood-to-plasma collector, a disposable capsule that contain test reagents for a specific biomarker and the Egoo smartphone app that operates the system and can share data with health authorities.
About Hipro
Hipro Biotechnology is a leading point-of-care company in China with sales to more than 14.000 hospital in China. The company provide first-in-class products to its customers in China and other parts of the world. Hipro focuses on R&D, manufacturing, sales and marketing, and relevant services for point-of-care products. Hipro has a production bases in Hebei Province, Beijing, Suzhou, Chengdu, Guangzhou, and recently launched 3.69 acres industrial park project in China Medical City. Hipro has an R&D Center in Silicon Valley, USA and instrument R&D Center in Freiburg, Germany,